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Carotid endarterectomy (CEA) remains the stan-
dard of care for the treatment of high-grade stenosis
of the extracranial carotid arteries.1,2 Recently, per-
cutaneous transluminal angioplasty with stenting
(PTAS) has been investigated as an alternative to
CEA. As technologic advances have been made, the
enthusiasm for this new procedure has increased.3-7
The rationale for the percutaneous approach to
carotid occlusive disease includes reduced morbidity
rates, improved long-term patency rates, theoretical-
ly reduced costs, and less anesthetic risks. A higher
rate of complications from angioplasty has been
reported when compared with CEA.8 A review of
the charges associated with these 2 procedures has
shown that CEA remains a less costly procedure.9
This review evaluates the early clinical results of
these 2 techniques for a subset of patients treated
with local anesthesia.
METHODS
A review was performed for all patients who under-
went elective treatment for carotid stenosis by means
of either CEA or PTAS with local or regional anesthe-
sia (LRA) between August 1994 and May 1997 at the
University of Alabama at Birmingham Hospital and
the Birmingham Veterans Administration Hospital.
The clinic notes, hospital charts, and computerized
registries were analyzed retrospectively for patient
characteristics, indications for procedure, neurologic
complications, and nonneurologic complications. The
A comparison of carotid angioplasty 
with stenting versus endarterectomy 
with regional anesthesia
William D. Jordan Jr, MD, David C. Voellinger, MD, Winfield S. Fisher, MD,
David Redden, PhD, and Holt A. McDowell, MD, Birmingham, Ala
Introduction: Percutaneous transluminal angioplasty with stenting (PTAS) has been con-
sidered a potential alternative to carotid endarterectomy (CEA) for stroke prevention.
Interventionalists have suggested that PTAS carries less anesthetic risk than CEA. The
treatment of carotid stenosis with local or regional anesthesia (LRA) allows direct
intraprocedural neurologic evaluation and avoids the potential risks of general anesthesia.
Methods: We retrospectively analyzed the clinical charts of 377 patients who underwent
414 procedures for the elective treatment of carotid stenosis in 433 cerebral hemispheres
with LRA between August 1994 and May 1997. Group I (312 hemispheres) underwent
PTAS, and group II (121 hemispheres) underwent CEA.
Results: The indications for treatment included the following: asymptomatic severe
stenosis (n = 272; 62.8%), transient ischemic attack (TIA; n = 100; 23.1%), and prior
stroke (n = 61; 14.1%). The early neurologic results for the patients in group I (n = 268)
included 11 TIAs (4.1%), 23 strokes (8.6%), and 3 deaths (1.1%). The early neurologic
results for the patients in group II (n = 109) included 2 TIAs (1.8%), one stroke (0.9%),
and no deaths. The total stroke and death rates were 9.7% for the patients in group I
and 0.9% for the patients in group II (P = .0015). The cardiopulmonary events that led
to additional monitoring were evident after 96 procedures in group I (32.8%) and 21
procedures in group II (17.4%; P = .002).
Conclusion: PTAS carries a higher neurologic risk and requires more monitoring than
CEA in the treatment of patients with carotid artery stenosis with LRA. The proposed
benefit for the use of PTAS to avoid general anesthesia cannot be justified when com-
pared with CEA performed with LRA. (J Vasc Surg 1998;28:397-403.)
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patients who underwent treatment for acute strokes or
who underwent percutaneous angioplasty without
stenting (PTAS group only) were not included in this
series. The patients were not randomized to treatment
groups, and the treatment modality was decided on
the basis of referral patterns and the choices of the
treating physicians.
PTAS was accomplished with a coaxial femoral
artery catheterization technique with local injection.
After percutaneous femoral access was obtained,
guiding catheters were positioned proximal to the
bifurcation to image the stenosis before an appropri-
ately sized balloon and stent wire were selected.
Stenoses were crossed with a guidewire and predilat-
ed with a balloon. All patients in this series received
at least 1 stent that was dilated with balloon inflation
at pressures of 10 to 16 atm.
CEA was performed with local injection, region-
al cervical block, or both. Electroencephalogram
monitoring and transcranial Doppler monitoring
were commonly used. Primary closure, Dacron patch
angioplasty, and internal carotid shortening were
used as determined by the surgeon. Postoperative
monitoring occurred in the postanesthesia care unit
or in the intensive care unit (ICU), as governed by
the treating team.
The patient characteristics reviewed were sex, age,
and pre-existing comorbidities, which included: coro-
nary artery disease, hypertension, smoking, and dia-
betes. The indications for the procedure were divided
into 3 groups: (1) asymptomatic, which included
global, nonlateralizing symptoms of dizziness, syn-
cope, or presyncope; (2) transient ischemic attack
(TIA), which included amaurosis fugax; and (3)
stroke. The neurologic event must have occurred
within 3 months before the procedure to be consid-
ered a symptomatic lesion.10 TIAs had to be resolved
within 24 hours, and strokes were classified as lasting
longer than 24 hours. Neurologic complications were
defined as either TIAs or strokes in the presence of lat-
eralizing neurologic signs. Minor strokes caused mini-
mal neurologic deficit that resolved with minimal or
no deficit at the 30-day examination. Major strokes
were defined as those deficits that lasted beyond 30
days and caused a change in the lifestyle of a patient.10
Additional cardiopulmonary monitoring was
classified according to the need for intervention as
related to physiologic changes after the procedure.
Specifically, most patients were not placed in an ICU
setting, but telemetry or frequent blood pressure
monitoring were sometimes required to treat labile
blood pressure or cardiac instability. Hypotension
and bradycardia were counted as complications if the
conditions were treated with additional intravenous
fluids, inotropic agents, or atropine. Other events,
such as neck or groin hematomas that necessitated
operative evacuation or transfusion, were classified as
requiring additional monitoring.
Statistical analyses were performed to compare
patient characteristics, indications for intervention,
and neurologic and nonneurologic results. The c 2
test with Yates correction for continuity and the
Fisher exact test, both 2-tailed, were used. The
Fisher exact test was used when predicted continuity
table cell values were less than 5. The Student t test
was used to compare the ages of the patients in both
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Table I. Patient characteristics
PTAS (n = 268) CEA (n = 109) P value
Male 184 (68.7%) 83 (76.1%) .147
White 244 (91.0%) 102 (93.6%) .476
Age 69 ± 10 68 ± 10 .568
Range 35 - 88 41 - 90
CAD 165 (61.6%) 65 (59.6%) .727
Hypertension 166 (61.9%) 63 (57.8%) .358
Smoking 116 (43.3%) 67 (61.5%) .001
Diabetes 61 (22.8%) 22 (20.2%) .584
Procedures 293 121
Cerebral hemispheres treated 312 121
PTAS, Percutaneous transluminal angioplasty with stenting; CEA, carotid endarterectomy; CAD, coronary artery disease.
Table II. Indications for treatment
PTAS CEA
(312 hemispheres) (121 hemispheres)
Asymptomatic 196 (62.8%)* 76 (62.8%)*
TIA 63 (20.2%) 37 (30.6%)
Prior CVA 53 (17.0%) 8 (6.6%)
PTAS, Percutaneous transluminal angioplasty with stenting;
CEA, carotid endarterectomy; TIA, transient ischemic attack; 
CVA, cerebrovascular accident.
*P = 1, in comparison of symptomatic and asymptomatic groups.
procedural groups. A P value of less than .05 was
judged statistically significant.
RESULTS
We identified 377 patients who underwent 414
elective procedures for the treatment of 433 carotid
stenoses with LRA either by PTAS or CEA between
Aug 1994 and May 1997. Table I outlines the patient
characteristics for each group, including a similarity
between typical risk factors that are associated with
patients who are treated for carotid stenosis.
Most patients underwent treatment of asympto-
matic lesions that were identified from the presence
of a bruit or from an investigation for nonlateralizing
signs of cerebral ischemia (Table II). The proportion
of patients who were symptomatic (37.2%) and
asymptomatic (62.8%) was identical in each group.
The neurologic results between the 2 groups var-
ied significantly, with a 9.7% total stroke and death
rate for the patients in group I versus a 0.9% total
stroke and death rate for the patients in group II
(Table III). If the stroke rate is considered on the
basis of the number of hemispheres treated, the total
rate drops to 8.7% for group I and 0.8% for group
II. The major stroke and death rate for group I was
2.6% (7 patients, 2 of whom were considered con-
tralateral to side of treatment), and no major strokes
or deaths occurred in group II. Twenty minor
strokes were evident in the PTAS group—19 ipsilat-
eral, 1 contralateral. All of these patients with minor
strokes had minimal neurologic deficits that lasted
more than 24 hours and were absent or minimal at
the 30-day evaluation. Transient events were also
more evident for the patients in group I (4.1%) as
compared with the patients in group II (1.8%). All
of these deficits resolved within 24 hours of the pro-
cedure. Two patients in the PTAS group had con-
tralateral postprocedural strokes—1 minor, 1 major.
These patients underwent additional PTAS to suc-
cessfully stabilize these new symptoms. These addi-
tional procedures were not counted in this series.
Ninety-six nonneurologic complications that
necessitated additional cardiopulmonary monitoring
were noted in 94 patients for PTAS (35.1%; Table
IV). Most commonly, hypotension and bradycardia
(87 patients) led to additional therapeutic interven-
tion. Twenty-one similar complications were noted
in 20 patients for CEA (18.3%; P = .002). Other
nonneurologic complications were evident in 20
patients for PTAS and 3 patients for CEA (Table V)
but did not lead to additional procedures or inten-
sive monitoring.
DISCUSSION
Although PTAS is being investigated as a poten-
tial treatment for carotid stenosis, comparability
must be established in several areas before accep-
tance as an alternative method. Any new therapy
should undergo scrutiny to evaluate its efficacy in
the light of its historical standard. Specifically, CEA
has been established as the appropriate therapy in
high-grade stenosis of extracranial carotid arteries.
PTAS cannot currently be recommended as a less-
costly lower-risk alternative to CEA. One argument
for the treatment of carotid stenosis with the percu-
taneous approach includes the avoidance of the risk
of general anesthesia. However, CEA has been
reported as a safe and effective procedure without
general anesthesia.11-13 We compared the results of
our surgical experience with CEA with LRA along
with the results for patients for PTAS, which is also
performed with local anesthesia.
As the population has aged, the demand for
operations on patients with more significant medical
comorbidities has increased, as has the desire to
decrease morbidity rates and lengths of hospital
stays. Therefore the resurgence of CEAs without
general anesthesia has occurred. One can argue that
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Table III. Neurologic results
PTAS PTAS CEA CEA
(268 patients) (312 hemispheres) (109 patients) (121 hemispheres)
Asymptomatic 231 (86.2%) 270 (86.5%) 106 (97.2%) 118 (97.5%)
TIA 11 (4.1%) 15 (4.8%) 2 (1.8%) 2 (1.7%)
Minor stroke 19 (7.1%) 20 (6.4%) 1 (0.9%) 1 (0.8%)
Major stroke 4 (1.5%) 4 (1.3%) 0 0
Death 3 (1.1%) 3 (1.0%) 0 0
Total strokes and deaths 26 (9.7%)* 27 (8.7%) 1 (0.9%)* 1 (0.8%)
PTAS, Percutaneous transluminal angioplasty with stenting; CEA, carotid endarterectomy; TIA, transient ischemic attack.
*P = .0015, in comparison of all strokes and deaths in the asymptomatic and TIA groups.
LRA may reduce additional complications, both
neurologic and nonneurologic, from the proce-
dure.12 In consideration of LRA for CEA and PTAS,
a lower stroke and death rate is seen in the CEA
group. There is also a lower rate of systemic physio-
logic changes that require an increased intensity of
monitoring (eg, vital signs or therapeutic methods).
Paradoxically, the CEA with LRA, although physi-
cally more invasive, is actually “physiologically” less
invasive than the PTAS with LRA.
Currently, PTAS is performed with a research-
guided Institutional Review Board protocol and
involves careful prospective neurologic monitoring.
This study includes additional retrospective review of
hospital charts and computerized database records to
further substantiate those results. The CEA group is
evaluated on a regular basis by the surgical team, and
intensive evaluation is done only in the presence of
neurologic changes. Although differences may appear
on the basis of the methodology of evaluation in these
2 groups, the presence of a neurologic change is easi-
ly identified in either group. The primary question for
those patients who suffer minor neurologic events is
the duration of the event. Even transient ischemic
events were more evident in the PTAS group as com-
pared with this CEA group. This may suggest that
there is a higher rate of any neurologic change after
the PTAS procedure. However, most of these minor
strokes had near complete recovery at the 30-day
evaluation. This may suggest that the ischemic event
that occurs at the time of the procedure is stabilized
and further ischemia is substantially reduced after the
procedure is complete. This initial phenomenon may
be related to embolization during the PTAS. We have
evaluated a smaller subset of patients and found a sig-
nificantly higher microembolization rate during the
PTAS procedure when evaluated with transcranial
Doppler monitoring.14
The total stroke and death rates between these 2
groups vary by an absolute rate of 8.8%. The low
stroke rate of patients in group II reflects the stan-
dard success of CEA.15 The major stroke and death
rate of patients in group I offers a potential useful-
ness for PTAS in symptomatic lesions that are not
surgically accessible or in patients in extremis from
acute neurologic events. The carotid surgeon then
must consider whether the CEA can be done at a
lower morbidity rate than PTAS before entertaining
an endovascular therapy for these patients.
All but one of the PTAS procedures at our insti-
tution have been done with local anesthesia. CEA is
accomplished with local or general anesthesia at our
institution. We have previously reported a total stroke
and death rate of 3.6% for CEA at our institution.8
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Table V. Minor complications that did not require
cardiopulmonary monitoring
PTAS CEA
(293 procedures) (121 procedures)
Increased creatinine of >0.5 (6) Cranial nerve injury (2)
Urinary tract infection (6) Aspiration pneumonia (1)
Hematomas not requiring 
transfusion (6)
Lower extremity ischemia (1)
Acute renal failure (1)
PTAS, Percutaneous transluminal angioplasty with stenting;
CEA, carotid endarterectomy.
Table IV. Nonneurologic complications that required cardiopulmonary monitoring
PTAS CEA
(293 procedures) (121 procedures)
Asymptomatic 196 (62.8%)* 76 (62.8%)*
Hypotension 68 5
Bradycardia 19 (1 permanent pacemaker) 1*
Hypertension 1* 3
Hematoma 1* 5
Congestive heart failure 0 3
GI bleeding 3 0
Anemia 1 2
Retroperitoneal hematoma 1 0
Myocardial infarction 1 0
Pulmonary edema 1 1
Atrial fibrillation 0 1
Total 96 (32.8%)† 21 (17.4%)†
PTAS, Percutaneous translumial angioplasty with stenting; CEA, carotid endarterectomy; GI, gastrointestinal.
*Patients with more than 1 complication.
†P = .002 in comparison of all monitored complications with the absence of complications.
This report reflects a subgroup with a lower stroke
and death rate (0.9%) that may be related to the anes-
thetic technique. This anesthetic choice is primarily
related to the patient, surgeon, and referring doctor’s
preferences. Therefore a selection bias exists in this
group because only those patients who are suitable for
a neck operation in the awake state are chosen. Those
patients with severe hearing disorders or with whom
the surgical team is unable to communicate usually
cannot tolerate a procedure in this fashion. There are
also those patients who are to be at extreme high risk
for a general anesthetic who are selected for CEA with
regional anesthesia. Regardless, both the patient at
high risk and and the patient at normal risk can under-
go CEA with LRA with an acceptably low complica-
tion rate. Similarly, there exists some selection bias in
the PTAS group. Patients who require general anes-
thesia, who undergo angioplasty without stenting,
and who undergo angioplasty for total occlusion are
excluded. These patients may represent a higher risk
group for postprocedure stroke (data not shown).
This report, instead, focuses on a subgroup of patients
who were treated for carotid stenosis with regional
anesthesia.
Nonneurologic complications are also an impor-
tant consideration in the treatment of patients with
carotid disease. We previously have reported a higher
rate of nonneurologic complications associated with
the percutaneous procedure in comparison with
CEA.8 PTAS can cause continued distension of the
carotid bulb, which can lead to pronounced brady-
cardia and hypotension. This phenomenon has also
been known to occur with patients for CEA but has
had minimal long-term sequelae. Two patients for
PTAS in this series were found to have severe brady-
cardic complications: 1 patient required a pacemaker,
and another patient had delayed bradycardia and
eventually died. The monitoring of these patients
after carotid treatment includes electrocardiogram
monitoring and blood pressure monitoring. Most of
these patients routinely were monitored in a non-
ICU setting after the procedure. Occasionally, addi-
tional monitoring was required and included ICU
care, telemetry monitoring, increased frequency of
checking the vital signs, or an interarterial catheter.
We found a higher requirement for monitoring in
those patients who underwent PTAS as compared
with CEA, which further shows that this percuta-
neous approach is a “physiologically” more invasive
procedure that requires more monitoring.
Other studies have shown that CEA with region-
al anesthesia is safe, effective, and less cost-
ly.12,13,16,17 In an evaluation of hospital charges,
PTAS is more costly than CEA.9 A percutaneous
approach to carotid stenosis cannot be justified to
avoid general anesthesia. This disease, instead, can
be treated by both percutaneous and traditional sur-
gical means with LRA. Furthermore, these data sug-
gest that CEA with LRA carries a significantly lower
neurologic risk in comparison with PTAS. The term
percutaneous implies that a procedure may be less
invasive as compared with open surgical techniques.
At times, a “less invasive” approach may be fraught
with a paradoxically higher complication rate than
the traditional standard therapy and should not be
embraced without extensive scrutiny.
CONCLUSION
PTAS carries a significantly higher neurologic
risk than CEA in the treatment of patients with
carotid stenosis with regional anesthesia. We do
not advocate the widespread application of PTAS
for a primary treatment of carotid bifurcation
stenoses. Instead, we reserve PTAS for specific sit-
uations in which surgical treatment is not appropri-
ate. Currently, we do not consider PTAS an accept-
able alternative to CEA, and therefore, we do not
support further clinical investigation in a random-
ized fashion to ascertain a similarity between these
2 groups. As techniques are further modified and
morbidity and mortality rates are reduced, further
clinical investigations may be warranted.
We acknowledge the contributions of Dr Gary Roubin
and Dr Sri Iyer, formerly of the Division of Cardiovascular
Disease, and of Dr Camilo Gomez, the Department of
Neurology.
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Dr G. Patrick Clagett (Dallas, Tex). There has been
an alarming increase in angioplasty and stenting for
carotid artery disease throughout the world. This has
occurred despite the proof of efficacy, safety, and durabil-
ity of the procedure. Therefore I applaud Dr Will Jordan
and his colleagues for trying to shed some light on the
problem in showing that carotid endarterectomy with
local anesthesia is a platinum standard and that angioplas-
ty by comparison looks like tarnished brass.
Despite my sympathy and yours—he is preaching to
the choir, after all—this report will not be convincing to
neurologists, internists, and others who care for these
patients. It is retrospective, nonrandomized, subject to
selection and interpretation bias, and not in agreement
with other data from the University of Alabama. Drs
Roubin and Yadav are prominent in their absence from the
lineup of authorship on Dr Jordan’s paper. Both have
recent reports in the cardiology literature that claim better
results from angioplasty and stenting. Dr Roubin claims a
99% technical success rate in 152 patients with no deaths
and 2 major strokes (1.3%), and Dr Yadav reports that in
107 patients who were considered at high risk for
endarterectomy, the incidence rate of major strokes and
deaths was 2.8%. In both reports, the incidence rates of
minor transient strokes were 5% to 7%. So, now we have
multiple reports from the same institution reporting dif-
ferent results. Are you and the cardiologists from the
University of Alabama reporting the same patients, and
why are the outcomes different? Are you including in your
analysis patients on the steep slope of the learning curve
for angioplasty and stenting that perhaps Roubin and
Yadav omitted from their reports? Was independent neu-
rologic assessment carried out on your patients and on
those undergoing angioplasty and stent placement? I am a
little disturbed by the large proportion of patients who
were asymptomatic in both groups, about two thirds of all
patients. Clearly, stroke and death rates in these ranges in
the angioplasty group outweigh any benefit in these
patients who were asymptomatic. My question asks what
was the stroke and death rate among the patients who
were symptomatic with 70% or greater stenosis? This is 
the group that hopefully will be studied in a randomized
trial comparing angioplasty and stenting with carotid
endarterectomy.
To date, we are left with retrospective data that show
that angioplasty and stenting are either good or bad
depending on your point of view and what journals you
have read. Even the same patients from the same institu-
tions have either good or bad results depending on who
you believe. I personally believe Dr Jordan because I know
him to be honest, forthright, and responsible. Others,
however, will believe Drs Roubin and Yadav and their dis-
ciples. How do we sort out this dilemma? It is a major
problem that will only continue to grow, not only at the
University of Alabama but throughout the country. This is
beginning to sound reminiscent of the arguments that
went back and forth between surgeons and neurologists in
favor of aspirin or carotid endarterectomy. It took a single,
randomized trial of 659 patients over 2 years to settle a
decade of bickering between surgeons, neurologists, and
others. It is truly amazing how quickly things are settled
in the cold light of science. Do you think that the same is
true with regards to angioplasty and stenting? Thank you.
Dr William D. Jordan. I think that Dr Clagett cut
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right to the quick of the problem. Perhaps it is the fact
that he is right—I do preach to the choir—but by the
same token, I hope that the choir knows the data, before
the choir confronts the heathen, and has an opportunity
to discuss the data with him.
I will try to answer some of your questions here.
Specifically, you mention the previous publications that
have come forth from the University of Alabama. I am
most familiar with the one that was published in 1997 in
which 107 patients were reported. I participated in the
review of that group. I think that if you read that paper
carefully—and I would encourage everyone who is inter-
ested in this topic to read that paper because the number
that is quoted is the major stroke and death rate—you will
find that all strokes and deaths are reported at a per-
patient rate of 9.3%. Because of that “per-artery” rate or
per-size rate and because sometimes in the cardiology lit-
erature there is a tendency to report results on the basis of
arteries rather than hemispheres or sides, you might say
that the stroke rate can be reduced to about 7.8%. And
you are also right. It depends upon how you look at a
major stroke versus a minor stroke. We still consider that
a stroke lasts longer than 24 hours. It is not a transient
ischemic attack. But it is a stroke, whether it be minor or
major.
I have not included “learning-curve” cases. The first 5
cases done at the University of Alabama in 1994 were
done without stents. Patient 5 had an acute thrombosis
that had to be reopened and then had subsequent cerebral
infarction and died. This patient is not included in the
series. And there have been selected cases that are done
without stents since that time. Those cases are typically
not reported, and I think it is because the angioplasty
without stent has suboptimal results.
You asked about the patients who were symptomatic,
and we did not have a formal breakdown of those patients
and their stroke rates. However, there was 1 stroke in the
endarterectomy group, and that occurred in a patient who
was symptomatic and who suffered a stroke after surgery.
There were 28 strokes and deaths in the angioplasty
group, and roughly half of those were in patients who
were symptomatic. So, that will give you some idea of the
patients who were symptomatic. They represent roughly
one third or more of the treated group, but they do have
a slightly higher stroke rate.
Finally, I think we have come to the issue of a random-
ized trial. I think that has become a point of controversy and
discussion in our own institution, and the 3 carotid surgeons
who are represented in this paper have been very close to the
angioplasty and stenting series. On the basis of our review of
the data, we do not want to randomize patients. I cannot
ethically tell my patient that I do not know which form of
therapy is better, which is partly because I have seen the
results of angioplasty. I realize that there are enormous pres-
sures, essentially a runaway train, in the community and in
the national community to proceed with this trial. There is
1 trial that is industry-sponsored and ongoing right now. I
do need to recall the words of Dr DeBakey when he was
asked to participate in the NASCET trial. He essentially said
“No, I know the results.” It perhaps took several years
before he was cleared. I can only say that I would hope to
stand on the shoulders of surgical giants and perhaps see
what is on the horizon. I will wait and see what the nation-
al community discovers on this issue. Thank you.
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